Quantum BioPharma's Novel MS Drug Candidate Targets Myelin Degradation in Growing $38.62 Billion Market

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a NetworkNewsAudio editorial highlighting its novel approach to treating multiple sclerosis (MS), a chronic neurodegenerative disease affecting millions worldwide. The audio press release, titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” accompanies a previously published editorial that underscores the pressing demand for therapies that go beyond symptom management. This comes as the global MS therapeutics market is projected to reach $38.62 billion by 2030, driven by an aging population and increasing prevalence of the disease.

At the heart of the feature is Quantum BioPharma’s lead candidate, Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath. The myelin sheath is the protective covering around nerve fibers that is progressively damaged in MS, leading to symptoms such as numbness, weakness, and impaired coordination. Unlike current treatments that primarily manage symptoms or reduce relapse rates, Lucid-MS aims to prevent, stop, and potentially reverse myelin degradation. This mechanism addresses a significant unmet need for disease-modifying treatments that can alter the course of MS, rather than merely alleviating its effects.

The company’s focus on myelin repair is a departure from conventional MS therapies, which often target the immune system to reduce inflammation. By directly protecting and regenerating myelin, Lucid-MS could offer a transformative approach for patients who have limited options, especially those with progressive forms of MS where neurodegeneration is more pronounced. Preclinical models have shown that Lucid-MS can prevent and reverse myelin degradation, providing a strong rationale for advancing into clinical trials.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. In addition to its MS program, Quantum has developed UNBUZZD, a product for alcohol misuse, and retains a 19.84% stake in Unbuzzd Wellness Inc., with royalty payments of 7% of sales until $250 million is reached, after which royalties drop to 3% in perpetuity. Quantum retains 100% of the rights to develop pharmaceutical and medical uses of similar products.

The NetworkNewsWire feature underscores the importance of Quantum BioPharma’s approach in a market where the need for effective MS treatments is growing. With the global MS therapeutics market expected to expand significantly, Lucid-MS could represent a breakthrough for patients seeking options that target the root cause of the disease. For more information about Quantum BioPharma, visit the company’s newsroom at https://nnw.fm/QNTM.